Associations of Systemic Health and Medication Use with the Enlargement Rate of Geographic Atrophy in Age-related Macular Degeneration
Overview
Authors
Affiliations
Background: The associations of geographic atrophy (GA) progression with systemic health status and medication use are unclear.
Methods: We manually delineated GA in 318 eyes in the Age-Related Eye Disease Study. We calculated GA perimeter-adjusted growth rate as the ratio between GA area growth rate and mean GA perimeter between the first and last visit for each eye (mean follow-up=5.3 years). Patients' history of systemic health and medications was collected through questionnaires administered at study enrolment. We evaluated the associations between GA perimeter-adjusted growth rate and 27 systemic health factors using univariable and multivariable linear mixed-effects regression models.
Results: In the univariable model, GA perimeter-adjusted growth rate was associated with GA in the fellow eye at any visit (p=0.002), hypertension history (p=0.03), cholesterol-lowering medication use (p<0.001), beta-blocker use (p=0.02), diuretic use (p<0.001) and thyroid hormone use (p=0.03). Among the six factors, GA in the fellow eye at any visit (p=0.008), cholesterol-lowering medication use (p=0.002), and diuretic use (p<0.001) were independently associated with higher GA perimeter-adjusted growth rate in the multivariable model. GA perimeter-adjusted growth rate was 51.1% higher in patients with versus without cholesterol-lowering medication use history and was 37.8% higher in patients with versus without diuretic use history.
Conclusions: GA growth rate may be associated with the fellow eye status, cholesterol-lowering medication use, and diuretic use. These possible associations do not infer causal relationships, and future prospective studies are required to investigate the relationships further.
Age-related macular degeneration: natural history revisited in geographic atrophy.
Broadbent E, Kunzel S, Pfau M, Schmitz-Valckenberg S, Fleckenstein M Eye (Lond). 2024; 39(2):217-227.
PMID: 39472501 PMC: 11751078. DOI: 10.1038/s41433-024-03443-0.
Ferreira A, Vilares-Morgado R, Lima-Fontes M, Falcao M, Falcao-Reis F, Carneiro A Clin Ophthalmol. 2024; 18:1381-1390.
PMID: 38770398 PMC: 11104444. DOI: 10.2147/OPTH.S461515.
Update on glial antibody-mediated optic neuritis.
Song H, Zhou H, Wei S Jpn J Ophthalmol. 2022; 66(5):405-412.
PMID: 35895155 DOI: 10.1007/s10384-022-00932-1.